MAP.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Diagnostics & Research

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$20M	+34.0%	$-0.01	$-0.01–$-0.01	—	1
2028	$28M	+43.4%	$-0.01	$-0.01–$-0.01	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 4 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-31	$-0.01	$-0.01	+0.0%
2026-02-25	$-0.01	$-0.02	-80.0%
2025-06-30	$-0.02	$-0.02	-7.8%
2024-12-30	$-0.02	$-0.01	+44.3%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MAP.AXMicroba Life Sciences Limited	$0.05	+0.00%	$39M	—
AGN.AXArgenica Therapeutics Ltd	$0.17	+2.94%	$22M	—
BDX.AXBCAL Diagnostics Limited	$0.07	+0.00%	$26M	—
EMD.AXEmyria Limited	$0.05	+10.64%	$30M	—
EYE.AXNova Eye Medical Limited	$0.13

Microba Life Sciences Limited

Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.

microba.com

Employees: 80
IPO / List date: Apr 5, 2022
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds MAP.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in MAP.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MAP.AX yet.